Second Quarter 2017 Financial Results and Operational Highlights Datum : 03/08/2017 @ 22h01 Quelle : Business Wire Name : Inotek Pharmaceuticals Corp. (MM) (ITEK) Kurs : 0.932 0.032 (3.56%) @ 21h55
https://de.advfn.com/p.php?pid=nmona&article=75380111 "we have decided to discontinue all preclinical and clinical development activities associated with trabodenoson in order to preserve our cash for value-creating opportunities,” said David P. Southwell, President and Chief Executive Officer of Inotek. “We continue to actively evaluate strategic alternatives to maximize shareholder value and are well-funded with $108.8 million in cash and marketable securities as of the end of the second quarter.”
"In conjunction with the FDC top-line results, Inotek also announced that it has engaged Perella Weinberg Partners as a financial advisor to assist the Company in exploring strategic alternatives."
|